Fierce Pharma November 9, 2023
In 2018, Hutchmed’s fruquintinib became the first domestically developed drug for a major cancer type to be approved in China. Five years later, the FDA has signed off on the VEGF inhibitor for adults with metastatic colorectal cancer (mCRC) as a third-line treatment.
Takeda pushed fruquintinib over the FDA finish line after acquiring its rights outside of China in January. The Tokyo company paid Hutchmed $400 million up front, with the potential for $730 million in milestone payments.
It will be known commercially as Fruzaqla and is for patients who have had chemotherapy, an anti-VEGF treatment and—if medically appropriate—an anti-EGFR therapy. The nod came three weeks ahead of its scheduled PDUFA date, making Fruzaqla the only selective inhibitor of all...
Today's Sponsors
Today's Sponsor